Anders Schelander

Anders Schelander is an experienced finance professional currently serving as a Finance Manager at Merz Therapeutics since March 2023. Previously, Anders held various significant roles at Novartis Sverige from January 2013 to March 2023, including Franchise Finance Head for the Nordic Neuroscience Franchise, where responsibilities encompassed divisional P&L management and analytical forecasting during critical product launches. Additional roles included Finance Head for the Novartis drug development organization and Nordic Project Manager for M&A activities involving the merger of Oncology drugs and divestment of Animal Health and OTC divisions. Earlier experience includes positions as a Business Planning Analyst at Novartis Sverige AB and Chief Financial Officer at Aktivhus AB, along with a Head of Business Intelligence role at SERGEL finance. Anders holds an Executive Master of Leadership & Management from Mguppen and a Magisterekonom degree in Accounting and Finance from Mid Sweden University.